Artemis Investment Management LLP Takes Position in IQVIA Holdings Inc. $IQV

Key Points

• Artemis Investment Management LLP opened a new Q4 position in IQVIA, buying 234,282 shares worth about $52.81 million, equal to roughly 0.14% of the company.
• Other large institutions also increased exposure—most notably Boston Partners added a new ~$676.7 million stake—leaving institutional ownership at 89.62%.
• IQVIA beat quarterly estimates (EPS $3.42 vs $3.40; revenue $4.36B vs $4.24B), set FY2026 guidance of $12.55–$12.85 EPS, and retains a consensus "Buy" rating with an average target of $226.63.

Artemis Investment Management LLP purchased a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 234,282 shares of the medical research company's stock, valued at approximately $52,810,000. Artemis Investment Management LLP owned about 0.14% of IQVIA as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently modified their holdings of the business. Boston Partners bought a new position in IQVIA during the third quarter worth $676,698,000. AQR Capital Management LLC raised its stake in IQVIA by 130.2% during the second quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company's stock worth $245,099,000 after buying an additional 879,701 shares during the last quarter. Citigroup Inc. raised its stake in IQVIA by 108.2% during the third quarter. Citigroup Inc. now owns 915,183 shares of the medical research company's stock worth $173,830,000 after buying an additional 475,557 shares during the last quarter. Cantillon Capital Management LLC raised its stake in IQVIA by 27.3% during the third quarter. Cantillon Capital Management LLC now owns 1,926,934 shares of the medical research company's stock worth $366,002,000 after buying an additional 413,256 shares during the last quarter. Finally, Invesco Ltd. raised its stake in IQVIA by 15.3% during the third quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company's stock worth $526,891,000 after buying an additional 367,204 shares during the last quarter. Institutional investors own 89.62% of the company's stock.

IQVIA Stock Down 0.4%

IQV opened at $157.73 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. The stock has a market cap of $26.77 billion, a price-to-earnings ratio of 20.07, a PEG ratio of 1.58 and a beta of 1.18. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $247.04. The company's 50-day moving average price is $169.36 and its two-hundred day moving average price is $201.57.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating analysts' consensus estimates of $3.40 by $0.02. The firm had revenue of $4.36 billion for the quarter, compared to analysts' expectations of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company's quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the company earned $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, equities analysts expect that IQVIA Holdings Inc. will post 11.5 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Truist Financial lowered their target price on shares of IQVIA from $290.00 to $245.00 and set a "buy" rating for the company in a research note on Thursday, February 19th. Jefferies Financial Group decreased their price target on shares of IQVIA from $270.00 to $255.00 and set a "buy" rating for the company in a research note on Friday, February 6th. Citigroup decreased their price target on shares of IQVIA from $230.00 to $200.00 and set a "neutral" rating for the company in a research note on Friday, February 6th. Royal Bank Of Canada initiated coverage on shares of IQVIA in a research note on Tuesday, March 3rd. They issued an "outperform" rating and a $221.00 price target for the company. Finally, Mizuho set a $215.00 price target on shares of IQVIA in a research note on Monday, February 23rd. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $226.63.

IQVIA Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.